Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Journey Medical Corp

DERM ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$6.72

▲ +1.05%

Market Cap $149.35M · Vol 91.98K

Key Metrics

P/E Ratio

N/A

FWD: 16.51

Market Cap

$149.35M

Micro Cap

Div Yield

N/A

EPS Growth

+94.15%

YoY

RSI (14)

61.44

Momentum

Beta

1.11

vs Market

52W High

$9.51

29.34% below

52W Low

$4.32

55.74% above

Volume

91.98K

Avg 64.64K

P/B

6.57

Price-to-book

ROE

N/A

Return on equity

Free Float

65.42%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Journey Medical Corp (DERM) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does DERM pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.51%

-5.62%

+5.83%

-13.07%

YTD

-12.84%

-7.44%

+212.56%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$61.86M
Net Income	$-11,431,000.00
Revenue Growth (YoY)	+23.33%
Gross Margin	59.29%
Operating Margin	-13.21%
Net Profit Margin	-18.48%
ROE	N/A
ROA · ROIC	-13.01% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	16.51
PEG Ratio	N/A
P/S	3.05
P/B	6.57
P/FCF	N/A
EPS Growth	+94.15%
Outstanding Shares	22.22M

Technical Indicators

50-Day SMA	$6.59
200-Day SMA	$7.02
RSI (14)	61.44
Beta	1.11
52-Week High	$9.51
52-Week Low	$4.32

Volume Today	91.98K
Avg Daily Volume (30D)	64.64K
Relative Volume	1.42x
Volatility (10D)	25.56
Volatility (30D)	48.57
Free Float	65.42%

Analyst Consensus

BUY

Current Price $6.72

Mean Target $14.00

52W Low$4.32 52W High$9.51

Current

Target

$4.32 $9.51

Current Analyst target

+108.33% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00ZWVDRL1

ISINUS48115J1097

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.